Consensus Recommendations to Accelerate Clinical Trials for Neurofibromatosis Type 2

200974 citationsJournal Articlebronze Open Access

Authors

D. Gareth Evans · Johns Hopkins University

Michel Kalamarides · National Cancer Institute

Kim Hunter‐Schaedle · Johns Hopkins University

Jaishri O. Blakeley · Johns Hopkins University

Jeffrey C. Allen · St. Mary's Hospital

Dusica Babovic-Vuskanovic · Children's Tumor Foundation

Allan J. Belzberg

Abstract

Both phase 0 and phase II NF2 trials are near-term options for NF2 clinical trials. The number of NF2 patients in the population remains limited, and successful recruitment will require ongoing collaboration efforts between NF2 clinics.

Topics & Keywords

Neurofibromatosis and Schwannoma Cases Meningioma and schwannoma management Bone Tumor Diagnosis and Treatments

UN Sustainable Development Goals

Industry, innovation and infrastructure

Publication Details

Published in: Clinical Cancer Research

Volume 15, Issue 16, pp. 5032-5039

DOI: 10.1158/1078-0432.ccr-08-3011

Field-Weighted Citation Impact: 4.64